Date published: 2025-10-30

1-800-457-3801

SCBT Portrait Logo
Seach Input

Ptpn23 Inhibitors

Chemical inhibitors of Ptpn23 can target various kinases and signaling pathways that are indirectly involved with the protein's functional role in dephosphorylation. Staurosporine, a known protein kinase inhibitor, can inhibit kinases responsible for phosphorylating substrates that Ptpn23 may act upon, thereby reducing the cellular pool of phosphorylated proteins available for Ptpn23 to dephosphorylate. Similarly, Bisindolylmaleimide I inhibits protein kinase C, leading to a decrease in substrate phosphorylation and, consequently, less engagement of Ptpn23 in signal transduction pathways. LY294002 and Wortmannin, both phosphoinositide 3-kinase inhibitors, can diminish the production of phosphatidylinositol (3,4,5)-trisphosphate (PIP3) and the activation of AKT, resulting in a reduction of AKT-mediated phosphorylation of proteins, which could be targeted by Ptpn23 for dephosphorylation. PP2, an Src family kinase inhibitor, and Dasatinib, a broad-spectrum tyrosine kinase inhibitor, can decrease phosphorylation levels of tyrosine residues on various proteins, reducing the interaction between these substrates and Ptpn23.

In addition to these kinase inhibitors, several chemicals target specific components of the MAPK signaling pathway. U0126 and PD98059 are both MEK inhibitors, which can reduce the activation of ERK and consequently limit the phosphorylation of ERK's substrates, potentially those dephosphorylated by Ptpn23. SB203580, a p38 MAP kinase inhibitor, and SP600125, a JNK inhibitor, operate similarly by inhibiting the phosphorylation of proteins involved in the stress response and other cellular processes, which may otherwise interact with Ptpn23. Triptolide, an inhibitor of transcription factors, can lead to reduced levels of proteins that require dephosphorylation by Ptpn23, thereby affecting the functional role of Ptpn23 by limiting its substrate availability. Lastly, Gefitinib, an EGFR inhibitor, can curtail the downstream phosphorylation events triggered by EGFR activation, ultimately reducing the pool of proteins that Ptpn23 might dephosphorylate in the signal transduction cascade. Each chemical, by influencing specific kinases or pathways, can alter the substrate landscape and the functional role of Ptpn23 in cellular signaling networks.

SEE ALSO...

Items 1 to 10 of 12 total

Display:

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Staurosporine

62996-74-1sc-3510
sc-3510A
sc-3510B
100 µg
1 mg
5 mg
$82.00
$150.00
$388.00
113
(4)

Staurosporine is a potent inhibitor of protein kinases. Although not selective, it can inhibit Ptpn23 by inhibiting kinases that phosphorylate substrates that Ptpn23 may dephosphorylate, thus reducing Ptpn23's availability to bind its substrates.

Triptolide

38748-32-2sc-200122
sc-200122A
1 mg
5 mg
$88.00
$200.00
13
(1)

Triptolide is known to inhibit several transcription factors and can indirectly inhibit Ptpn23 by reducing the levels of proteins that may require dephosphorylation by Ptpn23 for their activity, thereby decreasing Ptpn23's substrate pool.

Bisindolylmaleimide I (GF 109203X)

133052-90-1sc-24003A
sc-24003
1 mg
5 mg
$103.00
$237.00
36
(1)

Bisindolylmaleimide I is a specific inhibitor of protein kinase C (PKC). By inhibiting PKC, it can decrease phosphorylation of proteins that Ptpn23 would typically dephosphorylate, thus reducing Ptpn23's role in cellular signaling.

LY 294002

154447-36-6sc-201426
sc-201426A
5 mg
25 mg
$121.00
$392.00
148
(1)

LY294002 is a phosphoinositide 3-kinase (PI3K) inhibitor. By inhibiting PI3K, it can reduce the levels of PIP3 and subsequent AKT activation, leading to less phosphorylation of AKT substrates, which could be targets for Ptpn23.

Wortmannin

19545-26-7sc-3505
sc-3505A
sc-3505B
1 mg
5 mg
20 mg
$66.00
$219.00
$417.00
97
(3)

Wortmannin is another PI3K inhibitor that operates similarly to LY294002, leading to decreased AKT activity and subsequently reducing the phosphorylation of potential Ptpn23 substrates.

PP 2

172889-27-9sc-202769
sc-202769A
1 mg
5 mg
$92.00
$223.00
30
(1)

PP2 is an Src family kinase inhibitor. By inhibiting Src kinases, it could reduce the phosphorylation of proteins that Ptpn23 would act upon, thus reducing its functional role in the cell.

U-0126

109511-58-2sc-222395
sc-222395A
1 mg
5 mg
$63.00
$241.00
136
(2)

U0126 is an inhibitor of MEK1/2, which are upstream of ERK in the MAPK pathway. By inhibiting this pathway, there may be less phosphorylated ERK substrates for Ptpn23 to dephosphorylate.

PD 98059

167869-21-8sc-3532
sc-3532A
1 mg
5 mg
$39.00
$90.00
212
(2)

PD98059 is another MEK inhibitor, functioning similarly to U0126, potentially reducing the availability of substrates for Ptpn23 by inhibiting ERK phosphorylation.

SB 203580

152121-47-6sc-3533
sc-3533A
1 mg
5 mg
$88.00
$342.00
284
(5)

SB203580 specifically inhibits p38 MAP kinase. The inhibition of p38 MAPK can reduce the phosphorylation of substrates involved in stress response, which may otherwise be dephosphorylated by Ptpn23.

SP600125

129-56-6sc-200635
sc-200635A
10 mg
50 mg
$40.00
$150.00
257
(3)

SP600125 is an inhibitor of the c-Jun N-terminal kinase (JNK), which could reduce the phosphorylation of c-Jun, and other substrates, potentially reducing Ptpn23's substrate availability.